Impulse Dynamics’ Optimizer III
This article was originally published in The Gray Sheet
Developer of the cardiac contractility modulation (CCM) therapy for treatment of congestive heart failure completes enrollment in the 430-patient, FIX-HF-5 U.S. randomized clinical trial. The device resembles a pacemaker or implantable defibrillator, but instead of targeting heart rhythm it uses an electrical pulse to modulate the strength of heart muscle contraction (1"The Gray Sheet" Jan. 29, 2007, p. 11)...
You may also be interested in...
Impulse Dynamics is 80% enrolled in the U.S. pivotal trial of its Optimizer III cardiac contractility modulation therapy for the treatment of heart failure
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.